Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Disorders of Leukocytes01:27

Disorders of Leukocytes

1.1K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.1K
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

6.1K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
6.1K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

1.5K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
1.5K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

3.4K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
3.4K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

4.1K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
4.1K
Classification of Leukocytes01:30

Classification of Leukocytes

2.7K
Leukocytes are classified into two groups based on the presence or absence of cytoplasmic granules. Granular leukocytes, which contain granules, belong to the myeloid lineage and are divided into three subtypes: neutrophils, eosinophils, and basophils. These cells are roughly spherical and characterized by the granules in their cytoplasm.
Neutrophils are the most abundant type of granular leukocytes, comprising 50-70% of all leukocytes. They feature small, evenly distributed granules and a...
2.7K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome.

Blood advances·2022
Same author

Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.

Blood·2022
Same author

Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation.

Nature genetics·2022
Same author

Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia.

JAMA oncology·2022
Same author

Pediatric Cardio-Oncology Medicine: A New Approach in Cardiovascular Care.

Children (Basel, Switzerland)·2021
Same author

Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel.

Transplantation and cellular therapy·2021

関連する実験動画

Updated: Sep 12, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.1K

急性リンパ球白血病

Hagop Kantarjian1, Ching-Hon Pui2, Elias Jabbour1

  • 1Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Lancet (London, England)
|August 4, 2025
PubMed
まとめ

遺伝分析と標的治療の進歩により,急性リンパ球性白血病 (ALL) のアウトカムが著しく改善されました. 新しい治療法により 治癒率が高く 化学療法がより集中され 患者のケアが変わります

科学分野:

  • 血液学
  • 腫瘍学
  • 免疫療法

背景:

  • 急性リンパ球性白血病 (ALL) はリンパ系原始細胞の癌である.
  • 遺伝子解析により,40種類以上の ALL が特定されています.
  • 測定可能な残留病検定により,モニタリングとリスク分層が改善されました.

研究 の 目的:

  • ALL 治療の最近の進歩を振り返る
  • 分子療法と免疫療法の効果を 強調するためです
  • 大人および小児ALLの改善結果を議論する.

主な方法:

  • 分子療法と免疫療法における最近の突破のレビュー
  • チロシンキナーゼ阻害剤と抗体で治療されたBCR: ABL1陽性ALLにおけるアウトカムの分析.
  • 耐火性/再発性ALLにおけるキメリック抗原受容体T細胞治療の評価

主要な成果:

  • 新しい治療法により,ALLの治療効果が向上し,毒性が低下しました.
  • ティロシンキナーゼ阻害剤と標的抗体は,BCR:: ABL1陽性ALLにおいて前例のない結果を示しています.
  • B細胞ALLの全生存率は,成人と乳児でも80~90%に改善しました.

さらに関連する動画

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

11.6K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.6K

関連する実験動画

Last Updated: Sep 12, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.1K
Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

11.6K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.6K
  • CAR T細胞治療は,小児性不治性/再発性ALLのアウトカムを変えており,成人の最前線治療に使用されています.
  • 結論:

    • ALL の 治療 に おける 革新 は 治癒 率 を 増加 さ せる.
    • 集中化学療法や幹細胞移植への依存を減らすことが可能である.
    • 成人と乳児を含む様々な患者集団で改善された結果が達成されています.